No Improvement in OS, DFS With MP + Adjuvant ADT for High-Risk Prostate Cancer
The addition of mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy did not increase survival among patients with high-risk prostate cancer.
Diagnosis & Disease Information
Panobinostat vs Placebo: Patient-Reported Outcomes Comparable in Multiple Myeloma
Investigators sought to determine the impact on quality of life for patients with relapsed/refractory multiple myeloma treated with PAN and BTZ+DEX.
Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
[Breast Cancer: Targets and Therapy] Researchers present a review of the LHRH agonist triptorelin and the use of this agent to induce chemical castration in estrogen-sensitive breast cancer tumors in younger women.
Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer
In this open label phase 2 BOLERO-4 study, researchers evaluated the effect of everolimus plus endocrine therapy on progression-free survival.
Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.
5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
A report from a phase 3 study on the 5-year failure-free survival of women with endometrial cancer treated with radiation therapy alone vs chemoradiotherapy plus adjuvant chemotherapy.
Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
Data presented at the 2018 Gastrointestinal Cancers Symposium compared overall survival with cytoreductive surgery (CRS) alone for patients with gastric cancer and peritoneal carcinomatosis vs treatment with HIPEC plus CRS.
Better Postoperative Outcomes With RAMIE for Esophageal Cancer
Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.
Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
A metabolomics study of the effect of palbociclib/letrozole combination on cancer cells discovered that consumption of foods with certain xenoestrogens has a negative effect on the treatment.
FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...